Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 172139, 3 pages
http://dx.doi.org/10.1155/2014/172139
Case Report

Eltrombopag in Good’s Syndrome

1Department of Internal Medicine, Innlandet Hospital Trust, 2629 Lillehammer, Norway
2Department of Pathology, Oslo University Hospital, 0424 Oslo, Norway
3Department of Hematology, Oslo University Hospital, Rikshospitalet, P.O. Box 4950, Nydalen, 0424 Oslo, Norway

Received 20 May 2014; Revised 30 September 2014; Accepted 30 September 2014; Published 19 October 2014

Academic Editor: Ramon Tiu

Copyright © 2014 Håvard Anton Kristiansen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Good’s syndrome is a rare acquired immunodeficiency associated with thymoma. Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias. In this paper, we describe a male patient suffering from Good’s syndrome with immune-mediated T-cell driven pancytopenia and absence of megakaryopoiesis. He was successfully treated with eltrombopag resulting in a multilineage clinical response.